Research programme: cruzain inhibitors - ArQuleAlternative Names: Cruzain inhibitors research programme - ArQule
Latest Information Update: 03 Jan 2001
At a glance
- Originator ArQule
- Mechanism of Action Cysteine endopeptidase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Trypanosomiasis
Most Recent Events
- 03 Jan 2001 Discontinued-Preclinical for Trypanosomiasis in USA (Unknown route)
- 16 Sep 1999 New profile
- 16 Sep 1999 Preclinical development for Trypanosomiasis in USA (Unknown route)